• • • • • • • • • • • • • •

ACHIEVE HEALTH MANAGEMENT





Presentation of School Based Testing Programs for Detection of COVID-19

Achieve Health Management Presenters: Charles Parks, Chief Executive Officer Tadd Lazarus, MD, Chief Medical Officer

Inform Diagnostics Presenter: Patty Sipes, Chief Commercial Officer

CRISIS GO Presenter: Jim Spicuzza, Chief Product Officer **Contracted Supplier of COVID Testing Services for the Texas Department of State Health Services**





Achieve Health Management is a contracted supplier of as needed PCR COVID testing and rapid Antigen test kits for the Texas Department of State Health Services administered for Texas school districts by the Texas Education Agency

https://tea.texas.gov/texas-schools/health-safety-discipline/covid/covid-19-support-public-health-orders

Achieve Health Management is a *Clinical Services* company comprised of four divisions led by Principals with decades of innovative healthcare services experience across all channels and classes of trade



Achieve Care

Point of Care Solutions for Remote Physiological Monitoring in senior housing environments

- Point of Care RPM
- SNF, LTC, RCFE
- Hospitals
- Retail Rx



Achieve Clinical

Global Clinical and Administrative Call Center Services Provider

- Health Plans
- IPAs

٠

٠

- MSOs
 - RPM Companies



Achieve Diagnostics

Develops Strategic Alliances and Distribution Partnerships with Molecular Diagnostics Manufacturers

COVID-19 Testing



Achieve RPM Direct

Remote Physiological Monitoring Platforms, Devices and Services for Independent Physician Groups

- Independent Physicians
- Specialty Physician Groups




Specimen collection types and swab types for COVID-19 diagnostic testing

The following specimen and swab types are appropriate and offered by Achieve for SARS-CoV-2 testing:

Anterior nares specimen collected by an HCP or by onsite self-collection using a flocked swab, round foam swab, or spun fiber swab; or

Saliva specimen collected by an HCP or by onsite self-collection using a saliva collection funnel and tube.



Achieve Health Management provides comprehensive solutions for the range of COVID-19 testing needs

GeneFinder[™] COVID-19 PCR

- Guaranteed supply of GeneFinder[™] COVID-19 Plus Real*Amp* Tests -- FDA EUA
- Contracted CLIA-laboratory network for rtPCR
- Rapid Antigen testing on-site
- Collection kit supplies, training/in-service
- Results reported via HIPAA-compliant portal within 48 hours of specimen receipt

Specimen Collection Services

- Collection kit shipment to facilities (Anterior Nares swabs, Saliva and rapid Antigen tests)
- Pre-paid shipping labels provided
- Contracted medical staff to collect specimens (can be arranged by individual facility if needed)
- Funding provided by Texas DSHS



Preparation


Testing Day

Reporting

- 1. Establish testing objectives, timing and expectations
- 2. Conduct joint kick-off meeting and provide written statement of work
- 3. School will be responsible for providing space and other needs for test sites
- 4. Achieve will provide specimen collection kits, requisition forms and labels at testing locations
- 5. Achieve will provide medically trained and qualified staff to oversee the specimen collection process along with administrative support personnel
- 6. Testing and results reporting will be completed within 48 hours (business days only) within receipt of packaged samples
- 7. Test results will be provided to test recipients via online portal, phone, secure email or SMS text
- 8. Results reporting integrates with school SIS and staff directory services
- 9. Results will be reported to Federal, State, and Local health authorities, as mandated

CONFIDENTIAL

On-Site Testing Process Flow (Example)



COVID-19 Testing: PCR, Antigen, & Serology

There are three types of tests available for COVID-19 that can detect whether a person had it in the past (serology testing, which tests for antibodies against SARS-CoV-2, the virus that causes COVID-19), or whether they have it in the present (polymerase chain reaction (PCR) testing and antigen testing, which test for active infection). This document is designed to explain the differences between PCR, antigen, and serology testing, and when one test might be used over another. This document was adapted from the Texas Department of State Health Services.

Topic	PCR Test	Antigen Test	Serology Test
Why is the test used?	PCR (molecular) tests look for the genetic material of the virus itself in the nose, throat, or other areas in the respiratory tract to determine if there is an active infection with SARS-CoV-2.	Antigen tests look for pieces of proteins that make up the SARSCoV-2 virus to determine if the person has an active infection .	Serology looks for antibodies against SARS-CoV-2 in the blood to determine if someone has been infected in the past . Antibodies are formed by the body to fight off infections. IgM is the first antibody that is formed against a germ, so it appears on tests first, usually within 1-2 weeks. The body then forms IgG, which appears on tests about 2 weeks after the illness starts. IgM usually disappears from the blood within a few months, but IgG can last for years. Some antibody tests test for IgM and IgG, and some only test for IgG.

Торіс	PCR Test	Antigen Test	Serology Test		
How is the test performed?	In most cases, a nose or throat swab is taken by a healthcare provider, and that swab is sent to the lab for testing.	In most cases, a nose or throat swab is taken by a healthcare provider, and that swab is sent to the lab for testing.	In most cases, a blood sample is taken and sent to the lab for testing.		
	Testing can also be done with a Rapid Test in which results are available quickly, this is usually done within your doctor's office.	Testing can also be done with a Rapid Test in which results are available within 15 minutes.			
What does a positive test mean?	A positive PCR test means that the person being tested has the virus that causes COVID-19.	A positive antigen test means that the person being tested has the virus that causes COVID-19.	A positive antibody test means that the person being tested was likely infected with COVID-19 in the past and that their immune		
	People who first test positive should isolate for a minimum of 10 days after symptoms begin,	People who first test positive should isolate for a minimum of 10 days after symptoms begin, be	system developed antibodies to try to fight it off.		
	be afebrile (with no fever) for at least 24 hours and have symptoms improving. People with no symptoms should isolate for 10 days after the date of their test.	afebrile (with no fever) for at least 24 hours and have symptoms improving. People with no symptoms should isolate for 10 days after the date of their test.	There is no recommendation for isolation with a positive antibody test. If symptomatic, follow-up with a PCR or antigen test to determine if currently infected.		

ACHIEVE HEALTHMANAGEMENT

What does a	A negative molecular test means	A negative antigen test means that	A negative antibody test means that
negative	that the SARS-CoV-2 virus was not	SARS-CoV-2 viral proteins were not	the person may not have had COVID-
test mean?	detected. However, it doesn't rule	detected. However, it doesn't rule out	19 in the past. However, they could
	out infection prior to the virus being	infection prior to the virus being at a	still have a current infection, and the
	at a detectable level.	detectable level.	antibody test was collected too soon
			to give a positive result.
	You should continue a full 14-day	If there is still concern that a person	
	quarantine and monitor for signs	has COVID-19 after a negative	
	and symptoms of infection. If you	antigen test, then that person should	
	remain symptom-free, you may	be tested again with a PCR test.	
	reduce your quarantine period		
	from 14 days to 10 days. If you	You should continue a full 14-day	
	receive a negative result from a	quarantine and monitor for signs and	
	viral COVID-19 test (PCR or rapid	symptoms of infection. If you remain	
	antigen), you can reduce your	symptom-free, you may reduce your	
	quarantine to seven days. Your	quarantine period from 14 days to 10	
	test can be collected no earlier	days. If you receive a negative result	
	than 48 hours prior to your	from a viral COVID-19 test (PCR or	
	quarantine release date, so the	rapid antigen), you can reduce your	
	earliest you can be tested is day	quarantine to seven days. Your test	
	five from your exposure date. You	can be collected no earlier than 48	
	must continue to quarantine while	hours prior to your quarantine	
	awaiting test results.	release date, so the earliest you can	
	The CDC recommends that	be tested is day five from your	
	fully vaccinated individuals	exposure date. You must continue to	
	who remain symptom-free do	quarantine while awaiting test	
	not need to quarantine but should get tested for COVID-	results.	
	19 3-5 days following an	• The CDC recommends that fully	
	exposure and wear a mask in	vaccinated individuals who	
	public indoor settings for 14	remain symptom-free do not	
	days or until they receive a	need to quarantine but should get tested for COVID-19 3-5	
	negative test result.	days following an exposure and	
		wear a mask in public indoor	

ACHIEVE HEALTHMANAGEMENT

When is it	After stopping quarantine, you should watch for symptoms until 14 days after exposure. If you have symptoms, immediately self-isolate and contact your local public health authority or healthcare provider. Make sure to continue wearing a mask, stay at least 6 feet from others, wash your hands, avoid crowds, and take other steps to prevent the spread of COVID-19.	settings for 14 days or until they receive a negative test result. After stopping quarantine, you should watch for symptoms until 14 days after exposure. If you have symptoms, immediately self-isolate and contact your local public health authority or healthcare provider. Make sure to continue wearing a mask, stay at least 6 feet from others, wash your hands, avoid crowds, and take other steps to prevent the spread of COVID-19.	
when is it helpful?	 It can be used to determine who has an active infection. It can help identify people who are contagious to others. 	 It can be used to quickly determine who has an active infection. It can help identify people who are contagious to others. It is a less expensive than a molecular test. 	 It can identify people who had an infection in the past, even if they had no symptoms of the illness. It can help determine who qualifies to donate convalescent plasma. It is helpful on a population level to determine how many people may have been infected with COVID-19 in a community or region. It may be negative if it is used too close to the beginning of an infection, which is why it should not be used to detect active COVID-19 infection.

When is it not as helpful?	 It only helps determine whether a person has an active infection at the time of testing. It does not help determine who had an infection in the past. It also does not help determine which people who have been exposed to COVID-19 will develop active infection during the 2 weeks after exposure. In some people, the virus can only be found by PCR for a few days at the beginning of the infection, so the test might not find the virus if the swab is taken more than a few days after the illness starts. In some people, the virus can be found by PCR in the nose and throat for several weeks, longer than the time that they are contagious to other people. 	 molecular tests, meaning there may be false negative results. Negative tests should be treated as presumptive. If a healthcare provider is concerned that the 	
----------------------------------	--	--	--

Other Information to Help Determine Usefulness of a Test

When new tests come out, they are evaluated for how well they work. You may see the following terms used in reports about new tests.

<u>Sensitivity</u>: Sensitivity is sometimes called the "true positive rate." It measures how frequently the test is positive when the person being tested has the disease. For example, when a test has 80% sensitivity, the test detects 80% of patients with the disease (true positives). However, 20% of patients with the disease are not detected (false negatives) by the test.

<u>Specificity</u>: Specificity is sometimes called the "true negative rate." It measures how frequently the test is negative when the person being tested doesn't have the disease. For example, when a test has 80% specificity, the test correctly reports 80% of patients without the disease as test negative (true negatives). However, 20% of patients without the disease are incorrectly identified as testing positive (false positives) by the test.

<u>Positive Predictive Value</u>: Positive predictive value is a measure of how likely it is that a positive test is a true positive rather than a false positive. This is dependent on how many people in the population being tested have had the disease. When there are very few people in the population that have had the disease, then there is a higher chance that a positive test is a false positive. When there are many people in a population that have had the disease, then there is a higher chance that a positive test is a true positive.



Overview of InformDX

- Headquartered in Irving, Texas
- One of the largest independent pathology labs in the nation
- 1,300 practices and 2,500 providers
- 1.3 million+ specimens processed annually
- 4 state-of-the-art laboratories
- Well-established reputation
 - Accuracy rates among the highest in AP industry
 - 50+ fellowship-trained, subspecialty pathologists
 - Semi-academic approach
 - Consensus conferencing
 - Pathologist-to-clinician interaction







Our Subspecialties





COVID-19 Testing

• Our molecular team of expert technicians and pathologists can deliver definitive results for COVID-19 testing within 1-2 days.

Gastrointestinal Pathology

 Our comprehensive services can help diagnose a full range of GI conditions, including Crohn's disease and hepatitis.

Dermatopathology

• Our dermatopathology lab is one of the largest in the United States and uses ancillary testing and molecular diagnostics to aid in precision diagnoses.

Urologic Pathology

- Urologists trust our advanced, in-house testing and the highly detailed prostate biopsy reports we provide. **Hematopathology**
- We provide progressive molecular and antibody-based diagnostics, as well as advanced genetic testing.

Neuropathology

• We provide expert neuropathology services to hospitals and clinicians, including small fiber neuropathy testing, muscle and nerve pathology, brain and spinal cord pathology.





COVID-19 Testing through Inform Diagnostics

Molecular team of technicians and pathologists

Results within 24-48 hours of lab receipt

Offer molecular testing, which detects RNA from current virus

Use the QuantStudio[™] real-time PCR system for our own lab-developed SARS-CoV-2 RT-PCR Assay

Assay detects nucleic acid from the SARS-CoV-2 virus via

nasopharyngeal swab

oropharyngeal swab

saliva specimen

Over 85,000 tests performed since onset of virus

Page 1 of 2		• DIAGNOSTICS
PATIENT Case Number: Patient: Sample Patient Date Of Birth: Sex: MRN:	PHYSICIAN Sample Client, MD Address City, ST 00000 United States Phone	SPECIMEN Collection: DATE/TIME Received: DATE Date Reported: DATE Specimen Type: Nasopharyngeal Swab
RESULTS		
ASSAY Qualitative SARS-CoV-2 RT-PCR	RESULT Detected	METHODOLOGY RT-PCR
		the submitted specimen. Positive results are infection or co-infection with other viruses.
Medical Director: Michael Miller, D.O. METHODOLOGY This test is performed using nucleic acid e		Cotton Center Blvd, Phoenix, AZ, 85040, CLIA: 03D1064744,
for Disease Control and Prevention (CDC) Real-Time Reverse Transcriptase (RT)-PC		r SARS-CoV-2 testing. The RNA is subjected to qualitative
Real-Time Reverse Transcriptase (RT)-PC	CR using primers and probe specific for on not exclude the possibility of nucleic ack	v SARS-CoV-2 testing. The RNA is subjected to qualitative letecting the SARS-CoV-2 RNA.
Real-Time Reverse Transcriptase (RT)-PC Limitations: A result of Not-Detected does PCR inhibitors in the patient specimen, or Disclaimer: This test was developed and it (CDC). The performance specifications we cleared or approved, but has been authori laboratories certified under the Clinical Lab This test is only authorized for the duration	R using primers and probe specific for of not exclude the possibility of nucleic acid virus with mutation within the PCR targe is performance characteristics were esta re independently verified by Inform Diag zed by FDA under an Emergency Use A poratory Improvement Amendments of 1 of time the declaration that circumstance RS-CoV-2 virus and/or diagnosis of COV	r SARS-CoV-2 testing. The RNA is subjected to qualitative letecting the SARS-CoV-2 RNA. d concentration below the limit of detection, or the presence of tregion. bished by Centers for Disease Control and Prevention nostics for the intended use. This test has not been FDA uthorization (EUA). Testing in the United States is limited to
Real-Time Reverse Transcriptase (RT)-PC Limitations: A result of Not-Detected does PCR inhibitors in the patient specimen, or Disclaimer: This test was developed and it (CDC). The performance specifications we cleared or approved, but has been authori laboratories certified under the Clinical Lat This test is only authorized for the duration in vitro diagnostic tests for detection of SA	R using primers and probe specific for of not exclude the possibility of nucleic acid virus with mutation within the PCR targe is performance characteristics were esta re independently verified by Inform Diag zed by FDA under an Emergency Use A poratory Improvement Amendments of 1 of time the declaration that circumstance RS-CoV-2 virus and/or diagnosis of COV	ir SARS-CoV-2 testing. The RNA is subjected to qualitative letecting the SARS-CoV-2 RNA. d concentration below the limit of detection, or the presence of t region. bilished by Centers for Disease Control and Prevention nostics for the intended use. This test has not been FDA uthorization (EUA). Testing in the United States is limited to 988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. se exist justifying the authorization of the emergency use of
Real-Time Reverse Transcriptase (RT)-PC Limitations: A result of Not-Detected does PCR inhibitors in the patient specimen, or Disclaimer: This test was developed and it (CDC). The performance specifications we cleared or approved, but has been authori laboratories certified under the Clinical Lat This test is only authorized for the duration in vitro diagnostic tests for detection of SA	R using primers and probe specific for of not exclude the possibility of nucleic acid virus with mutation within the PCR targe is performance characteristics were esta re independently verified by Inform Diag zed by FDA under an Emergency Use A poratory Improvement Amendments of 1 of time the declaration that circumstance RS-CoV-2 virus and/or diagnosis of COV	ir SARS-CoV-2 testing. The RNA is subjected to qualitative letecting the SARS-CoV-2 RNA. d concentration below the limit of detection, or the presence of t region. bilished by Centers for Disease Control and Prevention nostics for the intended use. This test has not been FDA uthorization (EUA). Testing in the United States is limited to 988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests. se exist justifying the authorization of the emergency use of
Real-Time Reverse Transcriptase (RT)-PC Limitations: A result of Not-Detected does PCR inhibitors in the patient specimen, or Disclaimer: This test was developed and it (CDC). The performance specifications we cleared or approved, but has been authori laboratories certified under the Clinical Lat This test is only authorized for the duratior in vitro diagnostic tests for detection of SA 360bbb-3(b)(1), unless the authorization is	R using primers and probe specific for of not exclude the possibility of nucleic aci virus with mutation within the PCR targe s performance characteristics were esta re independently verified by Inform Diag zed by FDA under an Emergency Use A poratory Improvement Amendments of 11 of time the declaration that circumstance RS-CoV-2 virus and/or diagnosis of COV terminated or revoked sconer.	ir SARS-CoV-2 testing. The RNA is subjected to qualitative letecting the SARS-CoV-2 RNA. d concentration below the limit of detection, or the presence of t region. bilished by Centers for Disease Control and Prevention nostics for the intended use. This test has not been FDA uthorization (EUA). Testing in the United States is limited to 88 (CLIA), 42 U.S.C. 253a, to perform high complexity tests. es exist justifying the authorization of the emergency use of /ID-19 infection under section 564(b)(1) of the Act, 21 U.S.C.

Yun Wang, M.D., Ph.I DATE






Safety iPass 3.0 Vaccination and Testing



ABOUT CRISISGO

CUSTOMERS ARE OUR PRIORITY

- Founded in 2013
- 100% uptime over 3 consecutive years
 - Offices located in California and Missouri
 - Combined 90+ years of ed-tech experience in K12
 - Secure platform; cloud based and geo-redundancy
- AWS Public Safety and Disaster Response Partner





Global Technology Partner for Public Safety & Disaster Recovery









SAFETY IPASS

Mitigation tools to keeping students & staff safe





TEST MANAGEMENT





SEND EMAIL REGISTRATION FOR TESTING

Add Staff					Х		Edit Vendor		
Use the filters to searc	h for the targeted staff you want to add to t	he test.						ication Template	
Building:	All Buildings	Case: Choose whether case	e V Close	Contact: Choose wh	ether close contact			ed email notification will be en admin scheduled a test.	e automatically sent to the targe
							🖾 Email No	otification Template	Insert Custom Data V
Fully Vaccinated:	No V	Name/ID: Search name or ID			Reset Query		Hello,		
Query Result								e test is scheduled for the t iler link to fill all required inf	testee as below. Please click the formation on the form.
							Test Sch	neduler Link	
An ID is required to be	selected.						Test Appoin	tment Details	
Select all data							Benton Dist	rict	
Name 🌲	ID ÷	Building 🔶	Case	Close Contact	Fully Vaccinated				
Test Account	:	Benton District	No	No	No	Sear			
Adlai Adams		FirstNet	No	No	No				
Adlai Adams		FirstNet	No	No	No				
Tom Allen	98220023E	Benton District	No	Yes	No	1			
Driver App		Tower Grove High Sc		Vee 4 5 ··· 13 > 1	No 0 / page ⊻ Go to				6
						<			
				S	elected: 0 people Add				Back



REGISTRATION LIST

Safety CheckIn		Screening Tes	t					() H	Неір 😩 к	athryn Murphy
器 Tools	^	Staff St	udent	Visitor					Self-Appo	intment Link
Safety CheckIn		Make appointm	ents for the	targeted stur	dents that need to receive th	he test. You can	share the self-annointmen	t link with students or their	r quardians to all	low them
Safety iPass		to schedule a t	est appointm	ent on their o	own. Remember that studer dors or manually imported.				-	
Contact Listing				r++1						12.0
Test Management	^	Start date	→ End date		All Buildings V	II Grades	✓ All Vendors	✓ All Test Results	✓ Search n	ame or IDQ
Vendor		Bulk Appointme	ent	port Results	Export					
Consent Manageme	ent	Name 🌲	ID \$	Grade 🌲	Building 🌲	Appointment	Vendor 🌲	Test Time 🍦	Test Result	Action
Screening Test		Esther Howard	653518	1	Royal Maple Elementary	12/18/2021	Royal Maple Elementary	12/18/2020 01:40 AM	-	D B
iPass Management	*	Jacob Jones	449003	2	Royal Maple Elementary	07/28/2021	Royal Maple Elementary	07/28/2021 07:37 AM	Negative	e e
Dashboard ♀ Permission	v	Jane Cooper	558612	1	Royal Maple Elementary	07/09/2021	Royal Maple Elementary	07/09/2021 07:02 PM	Positive	C B
,								< 1 2 3 4 5 >	10/page ∨ G	Go to



MANUAL TEST RESULT

elect time
Cano




Х

TEST RESULTS

eening Test						•	Jim Spicuz:
aff Stude	ent Visit	tor				Self-	Appointment L
Make appointmer synced from vend			st. You can share the self-appoir	ntment link with staff to allow them to sch	edule a test on their own. After th	e test, the test results	can be
08/02/2021 ~ C	09/13/2021	13 Buildings Selected	Chieve Health Manag	All Tests Results All Tests Results No Result	∧ Search name or I	D Q	
Name 🍦	Staff ID 🌲	Building 🖕	Appointment Date 🍦	Vendor Vendor	Time 🌲	Test Result 🍦	Action
Jim Spicuzza	500410	Benton Park Elementary	08/26/2021	Achieve Health Management		No Result	ĐB
Jim Spicuzza	500410	Benton Park Elementary	08/29/2021	Achieve Health Management		No Result	D B
Jim Spicuzza	500410	Benton Park Elementary	09/02/2021	Achieve Health Management	09/02/2021 09:23 PM	Negative	D B
Jim Spicuzza2	23034	Tower Grove High School	08/26/2021	Achieve Health Management		No Result	D B
Jim Spicuzza2	23034	Tower Grove High School	08/29/2021	Achieve Health Management		No Result	D B
Jim Spicuzza2	23034	Tower Grove High School	09/02/2021	Achieve Health Management	09/02/2021 09:25 PM	Positive	D B
					< 1	2 > 10 / page 🗸	Go to




TEST DASHBOARD





VACCINATION MANAGEMENT



VACCINATION SURVEY





EMAIL & SUBMIT VACCINATION RECORD

		Staff Vaccination Record
To Be Verified 1 Completed Dasht	pard	Staff submit vaccination record for verification
Email Notification		You will be regarded as fully vaccinated after receiving either a two-dose mRNA COVID-19 vaccine single dose of Janssen COVID-19 vaccine. Please respond truthfully to following, and your admin v your submission.
Send email notification to 61 user(s) that awaiting va	cination record submission.	Vaccine Product Name
		Search name Q Pfizer-BioNTech vaccine (two-dose)
Email Subject		O Moderna vaccine (two-dose)
Staff Vaccination Record Request		Action Janssen/Johnson & Johnson's vaccine (single dose)
Notification Email Content		☐ Other
	Insert Custom Data 🗸	Fully Vaccinated Date Select Date
Hello Staff Name ,		■ Vaccination Site
Due to COVID-19, we have implemented the vaccina	on management process to protect our staff.	
If you are fully vaccinated, please click the report butt information.	n below to upload your vaccination record with the required	* Upload the scan copy of your COVID-19 vaccination record card +
Report		Handwritten Signature
If you have any questions or concerns, please contact	your supervisor for additional information.	
ABC Building		
		Upload you drivers license:
	Cancel Send	Attach Files +



CONTACT TRACING

Contact Listing			Help & Kathryn Murphy	
Staff Student Date: 10/10	0/2020 🖹 Building	: Frazier High School V		
New Daily Cases	Cumulative Cases	New Daily Close Contacts	Quarantined Close Contacts 64	
New Daily Case Trend Cumul	ative Case Trend	New Daily Close Contact Trend	Quarantined Close Contact Trend	
3	\sim	60 40 20		
0 00128 00121 00128 00129 00129 0010, 000	2,0103,0104,0105,0106,0101,0108,0109,1	0/10 0 00/20 00/20 00/20 00/20 00/20 00/20 00/20 00/20	02,000,000,000,000,000,000,000,000,000,	
	Close Contacts		Export	



Rapid contact tracing based on SIS, attendance, activities, vaccination status and testing.



In combination with quarantine & isolation management; Based on vaccine status and symptoms.

083

Contact tracing communication support, and guidance to test for rapid contact tracing and case identification.







IDENTIFY CASE – CAPTURE CLOSE CONTACTS

		Da	vid Silver (ID: 9	96220023)					
Er	Entry Method: () iPass Badge Scan Certification				t: 10/19/2020 ~ 10/23/2020 🗎 The person entered the building on: 10/22/2020, 10/21/2020, 10/20/2020, 10/19/2020				
Exp	posure Type: 🔿 Same	Building 🔵 Same Area 💿 Same Se	ction	Section:	8 sections			Reset	uer
Close Co	ontact Query Results								
Add Al	Il As Close Contact	Add Selected As Close Contact				All types	v	Search name or ID	
	Name 👙	Туре	ID ‡	Gra	ide Expo	sure Section		Action	
	Ryan Carson	Student	100099031	4		9/2020) History-861-4 0/2020) History-861-4			
	Bess Harrison	Student	100099030	4	(10/21	0/2020) History-861-4 1/2020) History-861-4 2/2020) History-861-4			
	Leroy Lawrence	Student	100099020	3	(10/21	0/2020) Science-238-3 1/2020) Science-238-3 2/2020) Science-238-3			
	Oscar Schultz	Student	100099029	4		9/2020) History-861-4 1/2020) History-861-4		园区	



EASILY MAINTAIN QUARANTINE

Use the filters to search for the targeted staff.	You can click the action icon to view more	details and change relevant state	uses.			
All Buildings	tine Expiration Date Case Statu	is V Clo	se Contact Status	ptomatic Status	Certification Status V	
Fully Vaccinated Status	st Result Search	Q				
Batch Edit Export						
lark as Case lemove Case Status	Close Contact Details	Symptomatic	Certification Status	Fully Vaccinated	Last Test Result	Action
lark as Close Contact lemove Close Contact Status	No	No	Uncertified	No	No Result	B
hange Symptomatic Status	No	No	Undefined	No	No Result	B
Angela Martin	No	No	Undefined	No	No Result	B
Archer Harold	No	No	Undefined	No	No Result	B
Assigned ItemsONLY	No	No	Undefined	No	No Result	B
Athena Campos	No	No	Undefined	No	No Result	B
Attendance Symptom Checker	No	No	Undefined	No	No Result	B
Ava Martin	No	Yes	Uncertified	No	No Result	B
Barry Watt	No	No	Undefined	No	No Result	B



MAINTAIN QUARANTINE RECORDS (Modified Quarantine)

Safety CheckIn	User List			Help	Kathryn Murphy	Kristin Watson		Х
册 Tools 🗸						Basic Informatica Status Summary	Area Entry Record Operation History	
iPass Management	Staff Student					Case Status		More Actions
User List	Use the filters to search for the t	targeted staff. You can click the action icon to vie	w more details and change relevant sta	tuses.		ls it a case? Yes	Quanrantining Yes (08/04/2021-08/18/2021)	
Badge Setting							Tes (06/04/2021-06/16/2021)	
🔟 Dashboard 🗸 🗸		Quanrantining V Case Status	✓ Close Contact State		tatus V	Close Contact Status		Details
"O Permission V	Certification Status V	Fully Vaccinated Status V	us ∨ Badge Status	✓ Search	Q	Is it a close contact?	Quanrantining	
	Email Notification Export					Close contacts of 2 people	Yes (08/06/2021-08/20/2021)	
	Name 🍦	Status ≑ Fully Vaccinated	Last Test Result	Badge Name	Action			
	Floyd Miles	No	Positive (07/03/2021)	Entry Denied	B	Symptomatic Status		Edit
		Ver			R	Symptom(s) present? Yes	Quanrantining Yes (08/06/2021-08/20/2021)	
	Cody Fisher	Yes	Negative (07/04/2021)	Entry		165	Tes (00/00/2021-00/20/2021)	
	Bessie Cooper	No	Negative (07/03/2021)	Entry	R	Certification Status		Details
	Jane Cooper	No	Negative (07/04/2021)	Quarantine	R	Certification Result	Certification Time	
	4		_		•	At Risk	07/03/2021 09:31AM	



VIEW LOG HISTORY

Jser List				(🤊 Help 🔹 k	Kathryn Murphy	Kristin Watson			×
Staff Student								tatus Summary Area	Entry Record	Operation History
Use the filters to search for the ta	argeted staff. You can click	the action icon to view n	nore details and change relevant s	statuses.			Robert Fox Edited the quarant	tine period of this person	n as case, and set	08/11 09:26 AM it to 08/04/2021-08/18/2021.
All Buildings	Quanrantining	✓ Case Status	✓ Close Contact SI	tatus V	Symptomatic Sta	tus V	Robert Fox Marked this persor	n as case, and set the qu	uarantine period to	08/11 09:21 AM o 08/04/2021-08/18/2021.
Certification Status V Email Notification Export	Fully Vaccinated Status	 ✓ Last Test Status 	 ✓ Badge Status 	v	Search	Q	Bessie Cooper Marked this persor	n as symptomatic, and se	et the quarantine	08/11 08:12 AM period to 08/04/2021–08/18/2021
Name 💠 S	itatus 🗘 Fu	ully Vaccinated	Last Test Result	Badge	Name	Action	Leslie Alexander		h farra	08/05 03:02 PM
Floyd Miles	No	0	Positive (07/03/2021)	Entry D	Denied	B	Comment: this pe	erson is symptomatic with	n lever.	
Cody Fisher	Ye	es	Negative (07/04/2021)	Entry		Q	Leslie Alexander			08/02 10:02 AM
Bessie Cooper	No	0	Negative (07/03/2021)	Entry		R	Marked this persor 08/04/2021-08/1		Robert Fox, and se	et the quarantine period to
Jane Cooper	No	0	Negative (07/04/2021)	Quaran	tine	B	Comment: this pe	erson is symptomatic with	h fever.	
4			_			•	Add Comment			



ACHIEVE HEALTHMANAGEMENT

Next Steps

- 1. If interested in on-site testing, please contact us at 1-(618) ACHIEVE or complete the online contact form at <u>HERE</u>
- 2. Schedule exploratory meeting with Achieve and CRISIS Go implementation team
- 3. Execute Master Service Agreement and Statement of Work